China In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai International Medical Center (SIMC) jointly established a Rehabilitation Medicine Center for stroke patients with the mission to bring and deliver German stroke rehabilitation treatment standards to patients in China. According to Consanas Rehabilitation, there are…
Boehringer Ingelheim With its brand new hub in Shanghai dedicated to research, business development and venture funding, German pharma giant Boehringer Ingelheim is taking a step further toward accessing innovation from the Chinese biotech industry. Boehringer Ingelheim has its sights set on establishing a deeper rapport with the Chinese biotech sector.…
AMR June 9th 2020 saw the launch of a new action fund on antimicrobial resistance (AMR), with 23 leading biopharmaceutical companies committing to almost USD one billion in investment to save collapsing antibiotic pipelines. The partnership aims to bring between two and four new antibiotics to patients by 2030 and facilitate…
Coronavirus A newly formed ‘Plasma Alliance’ of the world’s leading blood plasma companies believed that plasma from those who have recovered from COVID-19 could be a key piece of the puzzle in the fight against the unfolding global pandemic and speed up the search for an effective and accessible treatment. …
Coronavirus IFPMA Director General Thomas B. Cueni shares the outcomes of a recent high level pharma industry media briefing on the search for a COVID-19 treatment; highlighting the unprecedented levels of collaboration being demonstrated as key industry players work towards a common goal.* Last week, high-level representatives from seven companies…
Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…
Hungary In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of Health Insurance Fund Management (NEAK), explains, this has already had a significant impact on patient access to innovative new products.…
Hungary Francesco Banchi, general manager of Boehringer Ingelheim Hungary, elaborates on the successful development of the affiliate in recent years, making progress in new product reimbursement. As an experienced leader in sales and marketing, Banchi offers his insights into the challenging market access landscape of Hungary and his strategies in cooperating…
Hungary Attila Lukács, general manager Hungary, Romania, Bulgaria for CSL Behring outlines emergent trends in the Hungarian plasma medication market, how the affiliate has succeeded in becoming a partner to patient associations in Hungary, and his strategic priorities for the future. What I am most proud of is how we…
Pharma Faces 2019 saw Boehringer Ingelheim (BI) veteran Felix Gutsche take up his first country manager role – of a top-three affiliate, no less – after blazing a rather unorthodox path. From an International Trainee role at BI HQ, he moved into finance, where he stayed for a decade, with stints in…
Sweden Martin Tenlen was appointed as the general manager of the Nordics region for CSL Behring, the world’s fifth-largest biotech company, at the start of 2019. He highlights his priorities for leading the local affiliate, improving access to new treatments, leveraging Sweden’s innovation-friendly ecosystem through collaboration and strengthening the company’s leading…
Sweden Though far from the largest pharma market in Europe, Sweden nevertheless holds strategic importance for global pharma; from the country’s attitude to public health to its sophisticated digital framework, comprehensive patient registries and innovative spirit. Here, four pharma country managers hailing from outside Sweden’s borders give their first impressions of…
See our Cookie Privacy Policy Here